
The Global Exosome Market – Market Size, Forecast, Trials and Trends, 2023
Description
The Global Exosome Market – Market Size, Forecast, Trials and Trends, 2023
EXECUTIVE SUMMARYExosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells, since virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells.
Exosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.
The cargo contained within exosomes can offer prognostic information for range of diseases—including cardiovascular, renal, neurodegenerative, and metabolic diseases—as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.
Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient’s response to a specific course of treatment.
Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient’s exosomes can be isolated, modified with the appropriate siRNA or protein, and injected back into the patient for treatment. Numerous approaches are being researched for creating drug-loaded exosomes and exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.
For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits.
When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and China comes in second place. When the term “exosome” is searched in the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author. When the term “extracellular vesicles” is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Professor Giovanni Camussi.
To date, three pharma companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars. Within the past 5 years, there has been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions.
Globally, there are at least 204 clinical trials focusing on exosome-related studies. Of these, 114 trials are evaluating exosome-based therapeutics and 74 trials are testing exosome-based diagnostic tests. Currently, 93 of the exosome trials (45%) are observational studies and 111 of them (55%) are interventional studies. The exosome industry has also achieved two approvals of FDA-approved diagnostic tests: Bio-Techne’s ExoDx Prostate IntelliScore Test for prostate cancer and Guardant’s 360 CDx test for non-small cell lung cancer.
To characterize the rapidly expanding exosome market, BioInformant has released a 312-page global market report that explores growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. The report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials. It highlights information about exosome industry partnerships, merger and acquisition (M&A) activity, and financing events. It features company profiles for 118 global competitors from across the exosome marketplace. Importantly, it presents market size determinations by market segment with forecasts through 2030.
Today the exosome industry is witnessing:
A surging number of scientific papers investigating exosomes and their applications
Rising numbers of clinicals trials investigating exosome therapeutics and diagnostics
Swelling appetite among investors for exosome technology
An increasingly competitive IP environment
A diverse range of co-development partnerships
Proliferating numbers of exosome competitors in all major life science markets worldwide
This global strategic report about the exosome industry reveals:
1. The clinical pipeline for exosome therapeutics
2. Clinical trial activity by type, region, phase, and sponsor
3. Exosome industry events, including M&A activity, financing events, and IPOs
4. Strategic partnerships and co-development agreements
5. Competitors composing the global marketplace, including core technologies and products under development
6. Market size determinations by market segment, with forecasts through 2030
7. Exosome industry trends, competitive opportunities, and future directions
8. And so much more
With the competitive nature of this global market, you don’t have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research.
About BioInformant
With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 17+ years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine, as well as cited in Tony Robbins best-selling book, Life Force. Headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capitol Hill.
Table of Contents
312 Pages
- Statement of the Report
- Target Demographic
- Report Sources
- Purpose of the Report
- Executive Summary
- Introduction
- Structure of an Exosome
- Classification of Exosomes
- Biomedical Applications of Engineered Exosomes
- Functions of Exosomes
- Differences between Exosome Therapy and Cell Therapy
- Sources of Exosomes for Research
- Leveraging Exosomes as Biomarkers
- The Shift from Cell Therapy to Exosome Therapy
- Interior Modification
- Surface Modifications
- Comparison of Modification Methods
- Clinical Applications of Designer Exosomes
- Companies Developing Engineered Exosome-Based Therapeutics
- Cardiovascular Diseases
- Kidney Diseases
- Liver Diseases
- Wound Healing
- MSC Exosome-Based Clinical Trials for Regenerative Medicines
- Research to Inhibit Disease-Derived Exosomes
- Common Isolation Methods in Exosome Research
- Quality Control (QC) of Exosomes in Exosome Research
- Bioimaging Modalities used in Exosome Research
- Labeling Methods used in Exosome Research
- Determination of Exosome Dose in Exosome Studies
- Routes of Exosome Administration
- Characterization of Exosomes in Research
- Exosome Capture/Quantification Kits
- Exosome Standards
- Immunoplates for Capturing Exosomes
- Immunobeads for Exosome Isolation
- Exosome Marker Antibodies
- Trends in Global Publications
- Future in Exosome Research Publications
- Exosome Patent Assignees in 2021
- A Brief Overview of Current Exosome Patent Landscape
- Leading Assignees of Exosome Patents
- Exosome Patent/Patent Applications by Geography
- Legal Status of Exosome Patent/Patent Applications
- Assignee Categories
- Sources of Exosomes used in Clinical Trials
- Studies using Anti-Tumor Antigens
- Studies using Cytotoxic Drugs against Cancer
- Recruitment Status of Ongoing Exosome-based Clinical Trials
- Study Designs
- Study Phases
- Funding Types
- Exosome Clinical Trials by Geography
- Clinical Trials Involving MSC-Derived Exosomes
- Examples of Clinical Trials involving Drug-Loaded Exosomes
- Production of Exosomes from Cell Cultures
- Production Formats
- Companies Offering Exosome-Related Services
- Current Strategies for Exosome Isolation
- Differential Ultracentrifugation
- Ultrafiltration & Sequential Ultrafiltration
- Size-exclusion Chromatography
- Polymer Precipitation
- Immunoaffinity Capture
- Microfluidics-Based Techniques
- Commercially Available Exosome Isolation Kits
- Summary of Different Exosome Isolation Methods
- Characterization of Exosomes
- Microscopy and Nanoscopy for Exosome Imaging
- Direct Post-Isolation Labeling for Imaging
- Approaches for Exosome Analysis for Gene and Protein Biomarkers
- Emerging Optical Technologies for Exosome Analysis
- Emerging Electrochemical and Electromechanical Approaches
- Exosomal Cargo as Biomarkers for Disease Diagnosis
- Exosomal Proteins as Diagnostic Biomarkers
- Exosome Biomarkers in Pregnancy Disorders
- Exosome Biomarkers and Early Diagnosis of Immunologic Rejection
- Number of PubMed Articles on Exosome-Based Diagnosis
- Clinical Trials involving Exosome-based Diagnostics
- List of Commercial Companies Developing Exosome Therapeutics
- Advantages of Exosomes as Therapeutics
- Therapeutic Exosome Platforms
- Drugs Encapsulated in Exosomes
- Preclinical Studies involving Loaded Exosome Therapeutics
- Clinical Trials involving Exosome Therapeutics
- Exosome-Based Immunotherapy in Animal Models
- Ongoing Clinical Trials Involving Exosomes in Developing Vaccines
- The Shift from Cell Therapy to Exosome Therapy
- Clinical Applications of Exosomes
- Clinical Trials Focusing on Exosome-Based Diagnostics
- Therapeutic Applications of Exosomes
- Addreseable Diseases by Exosome Therapeutic Candidates
- Exosome-Based Vaccine Development
- Current Status of Exosome-Based Clinical Trials
- NIH Funding for Exosome Research
- Deals and Fund Raising in Exosome Space
- Current Industry Leaders in Exosome Sector
- The Four Categories of Exosome Companies
- Current Exosome Technologies by Commercial Companies
- Market for Exosome Therapeutics
- The Market for Exosome Diagnostics
- Market for Exosome Research Products
- 101 Bio
- Abbexa, Ltd.
- Abnova
- Adipomics, Inc.
- Aegle Therapeutics
- AgeX Therapeutics
- Aethlon Medical, Inc.
- Ambiotech
- AMS Biotechnology, Ltd. (AMSBIO)
- Anjarium Biosciences
- Antibodies-Online GmbH
- Aposcience AG
- Aruna Bio
- Avalon GloboCare Corp.
- Aviva Systems Biology
- Azymus Therapeutics
- Beckman Coulter Life Sciences
- BioCat GmbH
- BioFluidica
- Biological Dynamics, Inc.
- Biorbyt, Ltd.
- BioRegenerative Sciences, Inc.
- Bio-Techne
- BioVision, Inc.
- BrainStorm Cell Therapeutics
- BreStem Therapeutics, Inc.
- Capricor Therapeutics
- Carmine Therapeutics
- CD Bioparticles
- Cellarcus Biosciences, Inc.
- Cell Care Therapeutics
- Cell Factory BVBA/Esperite NV
- Cell Guidance Systems, Ltd.
- Ciola
- CK-Exogene
- Clara Biotech
- Codiak Biosciences
- Coya Therapeutics, Inc.
- Craif, Inc.
- Creative Bioarray
- CreativeBiostructure
- Creative Biolabs
- Creative Medical Technology Holdings
- Creative Proteomics
- Curexsys GmbH
- CUSABIO TECHNOLOGY LLC
- Diadem Biotherapeutics
- Direct Bio
- DLdevelop
- Entelexo Biotherapeutics
- EverZom
- Evomic Science LLC
- Evora Biosciences SAS
- Evox Therapeutics, Ltd.
- ExBiome BV
- Exrkine Corp.
- ExoCan Healthcare Technologies, Pvt. Ltd.
- ExoCoBio, Co., Ltd.
- Exogenus Therapeutics
- ExoPERT
- ExoPharm
- ExosomeDx (biotechne)
- ExosomePlus
- Exosome Sciences
- Exosomics S.p.A
- ExoVectory
- Florica Therapeutics
- GenWay Biotech, Inc.
- HansaBioMed Lifesiences, Ltd.
- ILIAS Biologics, Inc.
- Innocan Pharma
- Innovex Therapeutics, S.L
- INOVIQ, Ltd.
- Invent Biotechnologies, Inc.
- Izon Science, Ltd.
- Kimera Labs, Inc.
- Leading Biology, Inc.
- LifeSpan Biosciences, Inc.
- Lonza Group, Ltd.
- Mantra Bio
- MDimune, Inc.
- Miltenyi Biotech B.V. and Co., KG
- miR Scientific
- Mursla, Ltd.
- MyBioSource, Inc.
- NanoSomics, Inc.
- NanoView Biosciences
- NeurExo Sciences
- NeuroDex, Inc.
- NurExone Biologic Ltd
- New England Peptide, Inc.
- Norgen Biotek Corp.
- Novus Biologicals, LLC
- nRix Dx, Inc.
- Oasis Diagnostics Corporation
- OmniSpirant, Ltd.
- Organicell
- OriGene Technologies, Inc.
- Paracrine Therapeutics, Pvt. Ltd.
- QIAGEN
- ReNeuron
- RION
- RoosterBio, Inc.
- Rosetta Exosome
- Stemcell Medicine, Ltd.
- System Biosciences, LLC
- Tavec Pharma
- Theoria Science, Inc.
- Thermo Fisher Scientific
- TransGen Biotech, Co., Ltd.
- TriArm Therapeutics, Co., Ltd.
- United Therapeutics Corp.
- Versatope Therapeutics
- Vesigen Therapeutics, Inc.
- VivaZome Therapeutics, Pvt. Ltd.
- Xollent Biotech
- XOStem, Inc.
- YMAIR Genomics, LLC
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.